Our Leadership
The AltrixBio team combines deep scientific, operational, and commercial development expertise.
David Pass, Pharm.D.
CEO and President
Dr. David Pass brings over 25 years of extensive commercial success and deep clinical expertise across the therapeutic areas of diabetes, obesity, and cardiovascular disease. He previously led the Diabetes Franchise Alliance between Eli Lilly and Boehringer Ingelheim where he was instrumental in establishing and scaling a multi-billion-dollar franchise. He served as the COO and CCO at Gelesis, and just prior to joining AltrixBio he was president of Glooko’s Life Science business. His broad experience spans pharmaceuticals, medical devices, and innovative healthcare technology solutions. He has established a strong track record of driving commercial success and advancing patient care through a blend of scientific understanding, market acumen, and strategic partnerships.
David Maggs, MD
Chief Medical Officer
With over three decades at the intersection of endocrinology and pharmaceutical innovation, David brings unparalleled expertise in developing breakthrough diabetes and obesity treatments. His leadership roles at Warner Lambert, Pfizer, and Amylin Pharmaceuticals have shaped revolutionary therapies including GLP-1. In addition, he has metabolic and gut experience as chief medical officer at two companies with duodenal exclusion technologies. David holds an MBBS from the University of London and has been a practicing endocrinologist for decades.
Ella Kirby
SVP, Clinical Operations
Ella has over 20 years of experience leading global cross-functional teams in the clinical development of new drugs and devices. She has led the clinical operations for numerous companies from big pharma to medtech startups including Takeda, Lilly, Kadmon (acquired by Sanofi), and Fractyl. Skilled at implementing complex operational plans, running high quality studies, and leading successful regulatory filings in several therapeutic areas, including metabolic diseases.
Dylan Benningfield, MA
Senior Director, R&D and CMC
Dylan is an analytical chemist and expert in Chemistry, Manufacturing, and Controls (CMC), drug formulation, and scale-up, with more than a decade of experience working with polymers and diabetes oral-dose pharmaceuticals. He has applied his extensive knowledge and scientific approach at AltrixBio to define the formulation process and reaction variables that affect AJN003. Dylan is also responsible for adapting the AJN003 manufacturing process, enabling it to be scaled up from laboratory to clinical and commercial levels.
